Harmony Biosciences Holdings (HRMY) Accumulated Expenses (2019 - 2026)

Harmony Biosciences Holdings has disclosed Accumulated Expenses across 8 years of filings, most recently posting $1.9 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $1.9 million, down 93.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (down 93.54% YoY), and the FY2025 annual result was $65.8 million, up 630.19% from the prior year.
• Accumulated Expenses came in at $1.9 million for Q1 2026 at Harmony Biosciences Holdings, down from $65.8 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $72.8 million in Q3 2023 to a low of $1.9 million in Q1 2026.
• The 5-year median for Accumulated Expenses is $7.3 million (2024), against an average of $16.2 million.
• Across the five-year window, Accumulated Expenses soared 3028.16% in 2023 and plunged 93.54% in 2026, its largest moves.
• Harmony Biosciences Holdings' Accumulated Expenses stood at $25.4 million in 2022, then plunged by 90.72% to $2.4 million in 2023, then soared by 282.92% to $9.0 million in 2024, then surged by 630.19% to $65.8 million in 2025, then plunged by 97.1% to $1.9 million in 2026.
• The last three Accumulated Expenses figures came in at $1.9 million (Q1 2026), $65.8 million (Q4 2025), and $14.9 million (Q3 2025), per Business Quant data.